本刊在2014年第22卷第8期以附录形式转载了《中国2型糖尿病防治指南(2013年版)》,刊出后收到该指南制订的执笔者——陆菊明教授的勘误指示,对以下部分做出更正:1.附录9:删除“此外,血管紧张素转换酶抑制剂(ACEI)和血管紧张素II受体拮抗剂(ARB)类降压药在有效控制血压的同时,亦已被证实可显著降低新发糖尿病的风险”。2.附录9:“日本Kumomoto研究…”拼写有误,应为“日本Kumamoto研究…”。 This issue of the 22nd volume in 2014 twenty-eighth issue appendix in the form of “Guide to Prevention and Treatment of Type 2 Diabetes in China (2013 Edition)”, published after the guide issued by the author - Professor Lu Ju-ming, errata instructions, the following Part of the correction: 1. Appendix 9: Delete “In addition, angiotensin-converting enzyme inhibitor (ACEI) and angiotensin II receptor antagonist (ARB) class antihypertensive drugs in the effective control of blood pressure, it has been Proved to significantly reduce the risk of new onset diabetes ”. 2. Appendix 9: “Japanese Kumomoto Research ...” Spelling Wrong, Should Be “Japanese Kumamoto Research ...”.